The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
Integrating new technology into your practice can be a challenge, but Theia is here to share some secrets that can lead to success.
The Internet of Things (IoT) accelerates medical advancements, bringing much-appreciated improvements for patients and providers alike. Here are six ways in which IoT technology, such as the AdaptDx Pro guided by Theia, has recently benefited the medical field.
Plenty can change in the months between comprehensive exams, especially for our aging patients. Dr. Tammy Tully sleeps better at night knowing that she's detecting AMD as early as possible to prescribe proactive treatment to help preserve their vision.